Trophos

Trophos
Trophos
Type	Privately held company
Industry	research and development in biotechnology
Founded	Marseille, France (1999)
Founder	Christopher Henderson; Olivier Pourquie; Jean-Louis Kraus; Antoine Beret; Michel Delaage;
Defunct	2015
Fate	Acquired by Hoffmann-La Roche
Headquarters	France

Trophos was a biopharmaceutical company specialising in the discovery and development of novel therapeutics to treat both orphan neurodegenerative diseases and more prevalent disorders.^{[citation needed]}

Trophos was founded in 1999 in Marseille by three scientists: Christopher Henderson, Olivier Pourquie and Jean-Louis Kraus, and two entrepreneurs: Antoine Beret and Michel Delaage. Trophos' lead compound was olesoxime (TRO19622), a mitochondrial targeted compound developed to treat neurodegenerative diseases.

In January 2015, Hoffmann-La Roche announced its intention to buy Trophos for €120,000,000 upfront and up to €350,000,000 in milestone performance payments. The deal was completed shortly afterwards.

References

↑ Bordet, T.; Buisson, B.; Michaud, M.; Drouot, C.; Galea, P.; Delaage, P.; Akentieva, N. P.; Evers, A. S.; Covey, D. F.; Ostuni, M. A.; Lacapere, J.-J.; Massaad, C.; Schumacher, M.; Steidl, E.-M.; Maux, D.; Delaage, M.; Henderson, C. E.; Pruss, R. M. (2007). "Identification and Characterization of Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug Candidate for Amyotrophic Lateral Sclerosis". Journal of Pharmacology and Experimental Therapeutics. 322 (2): 709–720. doi:10.1124/jpet.107.123000. PMID 17496168. S2CID 17271734.
↑ "olesoxime". UKMi New Drugs Online Database. Retrieved 2 January 2016.
↑ "Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy". ClinicalTrials.gov. 5 February 2010. Retrieved 3 October 2010.
↑ "Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)". ClinicalTrials.gov. May 2010. Retrieved 3 October 2010.
↑ Franklin, Joshua (16 January 2015). "Roche buys France's Trophos to expand in neuromuscular disease". Reuters. Archived from the original on 15 December 2015. Retrieved 30 December 2015.
↑ Staff (15 February 2015). "Roche to Buy Trophos for Up-to-$543M". Genetic Engineering & Biotechnology News (paper). Vol. 35, no. 4. p. 6.

Rovini, Amandine; Carré, Manon; Bordet, Thierry; Pruss, Rebecca M.; Braguer, Diane (2010). "Olesoxime prevents microtubule-targeting drug neurotoxicity: Selective preservation of EB comets in differentiated neuronal cells". Biochemical Pharmacology. 80 (6): 884–894. doi:10.1016/j.bcp.2010.04.018. PMID 20417191.
Xiao, Wen Hua; Zheng, Felix Y.; Bennett, Gary J.; Bordet, Thierry; Pruss, Rebecca M. (2009). "Olesoxime (cholest-4-en-3-one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel". Pain. 147 (1–3): 202–9. doi:10.1016/j.pain.2009.09.006. PMC 2787910. PMID 19833436.
Bordet, T.; Buisson, B.; Michaud, M.; Abitbol, J.-L.; Marchand, F.; Grist, J.; Andriambeloson, E.; Malcangio, M.; Pruss, R. M. (2008). "Specific Antinociceptive Activity of Cholest-4-en-3-one, Oxime (TRO19622) in Experimental Models of Painful Diabetic and Chemotherapy-Induced Neuropathy". Journal of Pharmacology and Experimental Therapeutics. 326 (2): 623–632. doi:10.1124/jpet.108.139410. PMID 18492948. S2CID 33726393.

[1] Bordet, T.; Buisson, B.; Michaud, M.; Drouot, C.; Galea, P.; Delaage, P.; Akentieva, N. P.; Evers, A. S.; Covey, D. F.; Ostuni, M. A.; Lacapere, J.-J.; Massaad, C.; Schumacher, M.; Steidl, E.-M.; Maux, D.; Delaage, M.; Henderson, C. E.; Pruss, R. M. (2007). "Identification and Characterization of Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug Candidate for Amyotrophic Lateral Sclerosis". Journal of Pharmacology and Experimental Therapeutics. 322 (2): 709–720. doi:10.1124/jpet.107.123000. PMID 17496168. S2CID 17271734.

[2] "olesoxime". UKMi New Drugs Online Database. Retrieved 2 January 2016.

[3] "Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy". ClinicalTrials.gov. 5 February 2010. Retrieved 3 October 2010.

[4] "Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)". ClinicalTrials.gov. May 2010. Retrieved 3 October 2010.

[5] Franklin, Joshua (16 January 2015). "Roche buys France's Trophos to expand in neuromuscular disease". Reuters. Archived from the original on 15 December 2015. Retrieved 30 December 2015.

[6] Staff (15 February 2015). "Roche to Buy Trophos for Up-to-$543M". Genetic Engineering & Biotechnology News (paper). Vol. 35, no. 4. p. 6.

Trophos

References

Further reading